{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:02:40Z","timestamp":1793714560907,"version":"4.6.1"},"reference-count":123,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Measurable\/minimal residual disease (MRD) monitoring is an essential component of modern treatment protocols for ALL and AML. Early response to therapy, as measured by MRD levels at defined time points during treatment, serves as an important prognostic indicator and enables risk-adapted stratification with intensification of treatment for patients with poor response while potentially reducing therapy-related toxicity in those demonstrating excellent clearance of leukemic cells. MRD assays must be highly sensitive and specific; multidimensional\/parameter flow cytometry (MFC), quantitative polymerase chain reaction (qPCR), and next generation sequencing (NGS) are most used, while morphology is no longer the gold standard of response. MRD by MFC is used globally for risk and response in ALL and AML and is applicable to nearly 100% of patients with a sensitivity of 10\n                      <jats:sup>\u22124<\/jats:sup>\n                      . For ALL, immunoglobulin\/T-cell receptor rearrangements detected by qPCR or NGS offer a nearly universal target applicable to more than 90% of patients with B-ALL and up to 70% of patients with T-ALL with a sensitivity of 10\n                      <jats:sup>\u22125<\/jats:sup>\n                      . For AML, molecular testing is more frequently implemented in Europe and Asia than in the United States; however, the utilization of qPCR and\/or digital droplet PCR (dPCR) methodologies for high-risk fusions is evolving. NGS for somatic mutations are not yet routinely implemented for risk or response in pediatric AML, but continued advances in NGS technologies will continue to transform the MRD landscape of pediatric leukemias.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-516962","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:59:18Z","timestamp":1779998358000},"source":"Crossref","is-referenced-by-count":1,"title":["Measurable Residual Disease in Pediatric Acute Leukemia: Application and Interpretation of Current and Emerging Methodologies"],"prefix":"10.1200","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-4695","authenticated-orcid":true,"given":"Lisa","family":"Eidenschink Brodersen","sequence":"first","affiliation":[{"name":"Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA"},{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Kovach","sequence":"additional","affiliation":[{"name":"Departments of Laboratory Medicine and Pathology, Boston Children's Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0887-3709","authenticated-orcid":true,"given":"Jan","family":"Zuna","sequence":"additional","affiliation":[{"name":"Childhood Leukaemia Investigation Prague, Prague, Czech Republic"},{"name":"Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic"},{"name":"University Hospital Motol and Homolka, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1253"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0479-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21833"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002070"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.153"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14093"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14523"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4312"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04610.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2017.07.002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282424"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02083-9"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017003"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70124"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018923"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2115-8_6"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-017-0277-9"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000547423"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21528"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1414"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22944"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633685"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01086"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0669"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00494"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.237230"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02200"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00389"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-418-6_7"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806521"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248146"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-338707"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70206"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70600-9"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.6364"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02705"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.265"},{"key":"e_1_3_2_45_2","first-page":"e100545","article-title":"Implication of post-induction minimal residual disease in the management of pediatric acute lymphoblastic leukemia in a resource-limited setting","volume":"18","author":"Mushtaq W","year":"2026","unstructured":"Mushtaq W, Anwar S, Ahmad S, et al: Implication of post-induction minimal residual disease in the management of pediatric acute lymphoblastic leukemia in a resource-limited setting. Cureus 18:e100545, 2026","journal-title":"Cureus"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2023.10.001"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029611"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.08.007"},{"key":"e_1_3_2_49_2","first-page":"122","article-title":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial","volume":"111","author":"Balduzzi A","year":"2026","unstructured":"Balduzzi A, Glogova E, Peters C, et al: Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial. Haematologica 111:122-134, 2026","journal-title":"Haematologica"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.32063"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29715"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29562"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214171"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472778"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.10.014"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004008"},{"key":"e_1_3_2_59_2","article-title":"Optimizing blinatumomab access for low- and middle-income countries: Feasibility of a shortened, vial-sharing, outpatient approach for pediatric ALL","author":"Colunga PJE","unstructured":"Colunga PJE, G\u00f3mez-De Le\u00f3n A, Colunga Pedraza PR, et al: Optimizing blinatumomab access for low- and middle-income countries: Feasibility of a shortened, vial-sharing, outpatient approach for pediatric ALL. JCO Glob Oncol 10.1200\/GO-25-00469","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1656108"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1672509"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01576-3"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04601-0"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2590596"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21482"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324004"},{"key":"e_1_3_2_68_2","volume-title":"Validation of a Novel and Comprehensive Assay for B Lymphoblastic Leukemia Residual Disease Detection by Flow Cytometry Presented at International Clinical Cytometry Society (ICCS), Montreal, Canada; October 21\u201325","author":"Irani R","year":"2022","unstructured":"Irani R, Holmes B, O\u2019Gorman M, et al: Validation of a Novel and Comprehensive Assay for B Lymphoblastic Leukemia Residual Disease Detection by Flow Cytometry Presented at International Clinical Cytometry Society (ICCS), Montreal, Canada; October 21\u201325, 2022"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026655"},{"key":"e_1_3_2_70_2","first-page":"860","article-title":"False-positive and false-negative MRD results in children with acute lymphoblastic leukemia: Navigating between scylla and charybdis (brief review and clinical experience)","volume":"12","author":"Korkina YS","year":"2025","unstructured":"Korkina YS, Valiev TT, Batmanova NA, et al: False-positive and false-negative MRD results in children with acute lymphoblastic leukemia: Navigating between scylla and charybdis (brief review and clinical experience). Children (Basel) 12:860, 2025","journal-title":"Children (Basel)"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/1545-5017.70173"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209989"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2022-0172-OA"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466482"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2024.02.008"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749978"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01668-0"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212324"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677013"},{"key":"e_1_3_2_82_2","first-page":"533","article-title":"[Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression]","volume":"30","author":"Cho YU","year":"2010","unstructured":"Cho YU, Park CJ, Cha CH, et al: [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression]. Korean J Lab Med 30:533-539, 2010","journal-title":"Korean J Lab Med"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02120"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408336"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11784-4"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009534"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70090-5"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01841"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220962"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205666"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5323"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027904"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3064"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13107"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00327"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02075-9"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29313"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-878"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114579"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2548966"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024264"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03048"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70019"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071530"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026605"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02905-6"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764324"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018018945"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01157-w"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01397-w"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017837"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030775"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3826"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.113"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.010"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-261800"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01841"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02685-5"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071689"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0202"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032718"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000401"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180141"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02892"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-516962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:59:22Z","timestamp":1780430362000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-516962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-516962"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-516962","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e516962"}}